Patient Education · ADHD Medication
ADHD medication in India: what is available, and how it is prescribed
Most of what you read about ADHD medication online describes an American or British pharmacy shelf. In India the list is shorter and the prescribing rules are stricter. Knowing what is genuinely available, and why a chemist asks for a second copy of the prescription, makes treatment less confusing and considerably safer.
What Is Available
A shorter list
than the internet suggests
Indian guidance is direct about this: methylphenidate is the only stimulant marketed in India. Several widely discussed medicines, including lisdexamfetamine and mixed amphetamine salts, are not sold here at all. Reading foreign material and then asking for one of those medicines is a common and entirely understandable source of frustration.
| Medicine | Type | Marketed in India |
|---|---|---|
| Methylphenidate, immediate release | Stimulant | Yes |
| Methylphenidate, modified or extended release | Stimulant | Yes |
| Atomoxetine | Non-stimulant, noradrenaline reuptake inhibitor | Yes |
| Clonidine, immediate release | Non-stimulant, alpha-2 agonist | Yes |
| Guanfacine, including extended release | Non-stimulant, alpha-2 agonist | No |
| Lisdexamfetamine | Stimulant | No |
| Amphetamine salts | Stimulant | No |
Each available molecule is sold under several Indian brand names. The brand printed on the strip does not change the molecule, though release profile, strength and cost do differ between products, and supply is not uniform across cities. Availability also changes over time, so treat any list, including this one, as a starting point for a conversation rather than a settled fact.
Prescription Rules
Why the chemist keeps
a copy of your prescription
Methylphenidate occupies an unusual legal position in India. It is listed as a psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act 1985, and it is also a Schedule X drug under the Drugs and Cosmetics Rules 1945. Schedule X is the most tightly controlled prescription category in the country.
In practice this means the prescription must be written in duplicate, the pharmacy retains one copy for two years, and the medicine cannot be repeated, refilled or supplied on a telephone request. Only pharmacies holding the relevant licence may stock it. Atomoxetine and clonidine are ordinary prescription medicines and carry none of these restrictions.
Online Consultations
What can and cannot
be prescribed by video
This point is frequently misunderstood, and it matters. India’s Telemedicine Practice Guidelines set out a prescription matrix, and anything listed under Schedule X or the NDPS Act sits on the prohibited list. Methylphenidate therefore cannot be prescribed in a teleconsultation at all, whether it is a first appointment or a long-standing follow-up.
Assessment, formulation, second opinions, psychological treatment planning, review of response and monitoring discussions can all take place by video. Non-stimulant options such as atomoxetine are not on the prohibited list. But if a stimulant is the right treatment, an in-person consultation and a physical prescription are required. A service that offers to start you on methylphenidate entirely online is not following Indian rules.
If you are weighing up how much of an assessment can reasonably be done remotely, this article on online adult ADHD assessment in India covers the boundaries in more detail.
Guidelines and Reality
What guidance recommends,
and what the pharmacy stocks
NICE recommends lisdexamfetamine or methylphenidate as first-line medication for adults, with atomoxetine offered if stimulants cannot be tolerated or if symptoms have not responded to separate six-week trials of both stimulants at an adequate dose. For children aged five and over, methylphenidate is recommended first.
Because lisdexamfetamine is not marketed in India, and guanfacine is not either, Indian practice usually narrows to methylphenidate first and atomoxetine as the main non-stimulant alternative, with clonidine sometimes used as an adjunct. The Indian Psychiatric Society guideline, which sets out titration ranges for methylphenidate, atomoxetine and clonidine, works within the same constraint. This is a constraint of supply, not a judgement that the other medicines are unnecessary.
Medication is also not the automatic first step. NICE recommends medication for adults when significant impairment persists after environmental modifications have been tried and reviewed, and for children aged five and over only when impairment persists despite ADHD-focused support and environmental changes. For children under five, an ADHD-focused group parent-training programme comes first, and medication should not be started without a second specialist opinion.
Formulations
Short-acting and long-acting
solve different problems
Immediate-release methylphenidate typically begins to work within about an hour and wears off over roughly three to four hours, so it usually needs two or three doses a day. It is flexible, it makes the effect easy to observe, and it allows fine adjustment. Its drawbacks are the dosing burden, the mid-afternoon dip some people notice as it wears off, and the difficulty of taking a midday dose discreetly at school or work.
Modified-release preparations aim to cover a working or school day from a single morning dose, with a smoother profile and no midday dose to remember. They are less easily fine-tuned, cost more, and are not always in stock. Atomoxetine works differently again: it is taken daily, and any benefit builds over weeks rather than appearing on the first day, which matters if you are judging whether it is working.
The sensible question is not which formulation is best in the abstract but which hours of your day actually need cover, and what you can reliably take.
Dose
Higher is not
automatically better
A 2026 dose-effect network meta-analysis in Lancet Psychiatry examined how benefit changes with dose. For methylphenidate, efficacy peaked at around 45 mg a day in children and adolescents. In adults, efficacy continued to increase up to about 50 mg a day, but each further increment added progressively less benefit. Tolerability, meanwhile, worsened as doses climbed.
The practical implication is that the target is the lowest dose producing a real change in how your day works, not the highest dose you can physically tolerate. Doses are individual and are set by the prescribing clinician. Guideline ranges exist, but printing them on a public page invites self-adjustment. With a controlled medicine that is neither safe nor legal.
Before and During
What should be checked,
and how often
Before starting, NICE advises a full assessment including medical history, current medicines, height and weight, baseline pulse and blood pressure, and a cardiovascular assessment. A routine ECG is not required for stimulants, atomoxetine or guanfacine unless there are specific cardiac features in the personal or family history, or another medicine is already raising cardiac risk. Certain findings, such as sudden death in a first-degree relative under 40 suggesting a cardiac cause, fainting on exertion, or a murmur, warrant cardiology review before medication is started.
| Measure | Children and young people | Adults |
|---|---|---|
| Height | Every 6 months, plotted on a growth chart | Not required |
| Weight | Every 3 months up to age 10; at 3 and 6 months then 6-monthly over 10 | Every 6 months |
| Pulse and blood pressure | Before and after every dose change, and at least every 6 months | |
| Whether medication is still needed | Reviewed at least once a year | |
Side effects, what to report urgently and the questions patients most often ask about the heart and about dependence are covered separately in ADHD medication safety.
Practicalities
Supply, cost
and staying legal
Prices are not published here because they move. What is stable is that ADHD medication in India is usually paid for out of pocket, that modified-release products cost considerably more than immediate-release ones, and that brands of the same molecule are not priced alike. Supply is uneven, particularly outside large cities, and a pharmacy that stocked a product last month may not have it this month.
Two practical habits help. Ask your prescriber what to do if the usual product is unavailable, so that you are not improvising at the counter. And do not attempt to source controlled medicines through informal channels, courier them, or carry them across borders without documentation; the legal consequences in India are serious and entirely avoidable.
Care With Dr. Shaurya Garg
If this article
sounds familiar
If you have not yet had a formal assessment, this page explains how a clinician-led adult ADHD assessment works, and this article covers the conditions that most often imitate ADHD.
Dr Shaurya Garg provides structured ADHD assessment and treatment online across India and in person in New Delhi. Consultation fees are published here.
Sources & Further Reading
· NICE NG87: attention deficit hyperactivity disorder, diagnosis and management
· Government of India: list of Schedule H, Schedule III and Schedule X drugs under the NDPS Act
· Telemedicine Practice Guidelines for India, including the prescription matrix and prohibited list
Sources are provided for education and were reviewed on 28 July 2026. They do not replace individual clinical assessment.
Common Questions
ADHD medication,
answered plainly
Is Adderall available in India?
No. Mixed amphetamine salts are not marketed in India, and neither is lisdexamfetamine. Methylphenidate is the only ADHD stimulant available here, alongside the non-stimulants atomoxetine and clonidine.
Can a psychiatrist prescribe methylphenidate online in India?
No. India’s Telemedicine Practice Guidelines place Schedule X and NDPS-listed substances on the prohibited list, so methylphenidate cannot be prescribed in a teleconsultation at any stage. Assessment, review and non-stimulant treatment can be handled online, but a stimulant prescription requires an in-person consultation.
Why does the chemist ask for two copies of the prescription?
Methylphenidate is a Schedule X drug. The prescription must be issued in duplicate and the pharmacy is required to retain one copy for two years. The medicine cannot be refilled on the same prescription.
Is a brand-name product better than a cheaper one?
The molecule is the same. What genuinely differs is the release profile, the available strengths, cost and reliability of supply. Those are worth discussing with your prescriber; the brand name by itself is not.
Does everyone with ADHD need medication?
No. Guidance positions medication for adults when significant impairment remains after environmental modifications have been tried, and respects informed preference. Structured ADHD-focused psychological treatment is appropriate when medication is declined, not tolerated, or not sufficient on its own.